Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estrogen timing and growth hormone therapy for final height in girls with chronic kidney disease and delayed puberty
IRCT20201110049334N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ethinyl estradiol and somatropin in growth disorder, chronic kidney disease (CKD) and delayed puberty (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Final height after 15 years old. Started Mar 2014; status: completed.
02
Drugs
ethinyl estradiolsomatropin
03
Conditions
growth disorderchronic kidney disease (CKD)delayed puberty
Beyond the preview
Go deeper on IRCT20201110049334N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201110049334N1.